NCT01461746

Efficacy Study of Chemotherapy Followed by Radiation Therapy to Treat Endometrial Cancer

A Phase II Trial of Docetaxel/Cisplatin Chemotherapy Followed by Pelvic Radiation Therapy in Patients, With High-risk Endometrial Carcinoma After Staging Surgery

• Status: Unknown
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 67 (estimated)
• Sponsor: Asan Medical Center · Academic / Other
• Sex: Female
• Age: 20 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

Previous some studies suggested the addition of chemotherapy to radiation therapy after surgery may have survival benefit in patients with high risk endometrial cancer. In addition, docetaxel plus cisplatin regimen may have similar efficacy with paclitaxel plus carboplatin which is currently used in most cases. However, docetaxel plus cisplatin may cause less toxicity compared to paclitaxel plus carboplatin. Therefore, the investigators aimed to analyze the efficacy of docetaxel plus cisplatin regimen followed by radiation therapy after surgery in patients with high risk endometrial cancer.

Conditions

• Endometrial Cancer

Interventions

Type	Name	Description
DRUG	Docetaxel	Docetaxel 70mg/m2BSA, q 3 weeks, 3 cycles
DRUG	Cisplatin	Cisplatin 60mg/m2BSA, q 3 weeks, 3 cycles
RADIATION	Radiation therapy	Pelvic radiation therapy (Extended filed radiation therapy and addition of brachytherapy is allowed)

Timeline

• Start date: 2011-10-01
• Primary completion: 2017-12-01
• Completion: 2017-12-01
• First posted: 2011-10-28
• Last updated: 2017-05-31

Locations

1 site across 1 country: South Korea